Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis
MWN-AI** Summary
Aurora Cannabis Inc. (NASDAQ: ACB), a leader in the global medical cannabis sector, is set to ring the Nasdaq closing bell on February 18, 2026. This momentous event will be led by CEO and Executive Chairman Miguel Martin, along with members of the company's Board of Directors and executive leadership team. The ceremony is a celebration of Aurora's commitment to expanding its global medical cannabis strategy, reinforcing its position in key international markets.
Miguel Martin stated, "As we advance our global medical strategy, this moment at Nasdaq underscores our longstanding commitment to serving patients worldwide." He emphasized that the medical division is the primary driver of Aurora's growth, reflecting significant progress made in increasing the accessibility of cannabis for patients globally.
The closing bell will be broadcast live beginning at 3:45 PM ET, with the actual ringing scheduled for 4:00 PM ET. Viewers can watch the live stream through Nasdaq's official channels.
Aurora Cannabis is dedicated to improving lives through its scientific expertise and deep commitment to patient care, with operations in Canada, Europe, Australia, and New Zealand. The company, known for its portfolio of trusted brands—including Aurora, MedReleaf, and Pedanios—strategically focuses on high-margin opportunities with a medical-first approach. Furthermore, it maintains a controlling interest in Bevo Farms Ltd., a prominent supplier of propagated agricultural plants, further diversifying its operations.
As Aurora continues to navigate the complexities of the cannabis industry, this bell-ringing event symbolizes not just a celebration of past achievements but also a commitment to future growth in the evolving landscape of global medical cannabis.
MWN-AI** Analysis
As Aurora Cannabis Inc. prepares to ring the Nasdaq closing bell on February 18, 2026, the event symbolizes more than just a celebratory milestone; it represents a critical juncture for investors looking to capitalize on the burgeoning medical cannabis market. CEO Miguel Martin's emphasis on a medical-first strategy underscores Aurora's commitment to positioning itself as a leader in the global healthcare segment of the cannabis industry.
Aurora's alignment with medical applications of cannabis is an astute move, given the increasing legalization and acceptance across various jurisdictions. Investors should note that the company's diverse portfolio, which includes several trusted brands, provides a strong foundation for sustained growth. With a focus on high-margin opportunities in international markets, Aurora is well-poised to benefit from a projected expansion in demand for medical cannabis products.
Despite the current volatility often associated with cannabis stocks, Aurora’s GMP-certified manufacturing facilities and strategic partnerships contribute to an operational advantage, ensuring consistent product quality. As the company continues to broaden its global footprint, investors should watch for key developments and regulatory changes that could impact market dynamics.
However, potential investors should remain vigilant regarding inherent risks, including regulatory uncertainties and market competition. Aurora's reliance on its medical segment as a growth driver may also expose the company to fluctuations in patient demand and the evolving landscape of healthcare regulations. A thorough risk assessment is crucial for understanding the full scope of investment potential.
In summary, while Aurora's impending Nasdaq bell-ringing event signals positive momentum towards its strategic goals, careful consideration of market conditions and regulatory frameworks is essential for investors looking to engage with the company moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
NASDAQ | TSX: ACB
EDMONTON, AB, Feb. 12, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the company will ring the Nasdaq closing bell on Wednesday, February 18, 2026, at the Nasdaq MarketSite in New York's Times Square.
The ceremony will be led by Aurora's CEO and Executive Chairman, Miguel Martin, alongside a representative of the company's Board of Directors, executive leadership team and other employees. This event celebrates Aurora's evolution into a medical-first, globally focused cannabis company and strengthened position in key international markets.
"As we advance our global medical strategy, this moment at Nasdaq underscores our longstanding commitment to serving patients worldwide," said Miguel Martin, CEO & Executive Chairman for Aurora. "Our medical business is the clear driver of Aurora's growth and today's milestone reflects the tremendous progress we've made in opening the world to cannabis, and the exciting opportunities still ahead."
The Closing Bell ceremony will be broadcast live beginning at 3:45 p.m. ET, with the bell scheduled to ring at 4:00 p.m. ET, and streamed across Nasdaq's official channels. To view the live broadcast, visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information?
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming Nasdaq bell-ringing ceremony, the advancement of the Company's global medical cannabis strategy, the medical cannabis business as a driver of growth for the Company, and future growth opportunities.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2026/12/c3809.html
FAQ**
How does ringing the Nasdaq closing bell on February 18, 2026, demonstrate Aurora Cannabis Inc. ACB's commitment to its global medical cannabis strategy?
What key milestones has Aurora Cannabis Inc. ACB achieved that position it as a leader in the global medical cannabis market?
How does Aurora Cannabis Inc. ACB plan to expand its high-margin opportunities in international markets following this milestone?
In what ways will the bell-ringing ceremony highlight Aurora Cannabis Inc. ACB's dedication to patient care and quality in its product offerings?
**MWN-AI FAQ is based on asking OpenAI questions about Aurora Cannabis Inc. (NASDAQ: ACB).
NASDAQ: ACB
ACB Trading
-0.57% G/L:
$3.475 Last:
255,556 Volume:
$3.45 Open:
